Mission statement

Swiss Association of Perinatal Pharmacology (SAPP), 6.12.2007

1. The definition of perinatal pharmacology

Perinatal pharmacology comprises the impact of substances (drugs and medications, including those found in alternative medicine, vaccines, diagnostics, food supplements, abusing substances, pollutants, ionizing radiation) in pregnant women, nursing mothers, the unborn child, the premature, the newborn baby and the breastfed baby.
Subareas include the following (among others):

  • Teratology
  • Pharmacokinetics, -dynamics and -genetics in the pregnant/nursing woman, in the premature, the newborn baby and the breastfed baby
  • The tolerance of drugs and medications in pregnant/nursing women, the premature, the newborn baby and the breastfed baby
  • The optimization of the application of drugs with respect to nursing times
  • The risk/benefit evaluation of synthetic medications and their dosages with regard to the complaints most frequent associated with pregnancy and lactation
  • The risk/benefit evaluation of synthetic medications and their dosages with regard to the complications most frequently associated with pregnancy and lactation
  • Risk/benefit evaluation of synthetic medications (including vaccines and diagnostics) and their dosages for diseases not related to pregnancy or lactation
  • Risk/benefit evaluation for alternative medicine suitable in pregnancy and lactation
  • The substitution of vitamins, trace elements and mineral compounds
  • The importance of nutritional supplements for pregnant and nursing women
  • The significance of pollutants for pregnant and nursing women and the breastfed baby. The significance of abusing substances for the pregnant and nursing women, the premature, the newborn baby and the breastfed baby.

2. The Role of SAPP

In accordance with its Articles of Association SAPP promotes the knowledge and distribution of information on the impact of substances (drugs and medications including those found in alternative medicine, vaccines, diagnostics, food supplements, abusing substances, pollutants, ionizing radiation) in pregnant women, nursing mothers, the unborn child, the premature, the newborn baby and the breastfed baby. SAPP views itself as a link between pharmacy, medicine (gynaecology, neonatology, anesthesia, etc.), between practice, clinic, research and the legal authorities.

The objectives of SAPP

SAPP gathers existing and promotes new knowledge in the area of perinatal pharmacology. SAPP connects the interests of specialists in healthcare (pharmacists in the dispensary, physicians in practice, in research as well as in the legal authorities). New information is regularly provided to them in the form of publications and continuing education. The SAPP promotes the concerns of the perinatal pharmacology in all institutions of the Swiss health system, in particular
Swissmedic (Pharmacovigilance departments – among others)

  • Federal Office for Healthcare (BAG)
  • Swiss Teratology Information Service (STIS)
  • Swiss Medical Association (Foederatio medicorum helveticorum (FMH))
  • Swiss Society for Gynaecology and Obstetrics (SGGG)
  • pharmaSuisse (=Swiss Association of Pharmacists )
  • Universities, primarily medical and pharmaceutical schools and their faculties.

The SAPP promotes research on the use of substances in pregnant and nursing women with the help of international contacts at:

  • Swiss universities
  • Swiss research programs
  • Manufacturers of drugs.

The SAPP promotes evidence-based therapy for diseases during pregnancy and lactation.
The SAPP investigates the use and safety of “off label use” in pregnancy and lactation.
The SAPP encourages the formation of international networks on the use of substances by pregnant and nursing women.
The SAPP provides for ongoing education in perinatal pharmacology for physicians and pharmacists as well as interested scientists.
The SAPP is actively involved in the expansion of perinatal pharmacology in both medical and pharmaceutical education.
The SAPP promotes awareness in women of childbearing age of their exposure to medications and other substances prior to conception, in pregnancy and during lactation.

4. Activities

towards the achievement of the objectives SAPP collaborates with institutions concerned with perinatal pharmacology (e.g. Swissmedic, STIS)

  • It seeks contact with teaching and research
  • SAPP participates in studies and scientific publications and promotes them
  • SAPP offers education in perinatal pharmacology
  • It organizes meetings and publishes the results in the media
  • SAPP participates in health policy consultations and discussions.

Approved on 6th of December 2007 by the founding members of SAPP.

Zurich, 6th December 2007 / english version created 23rd August 2010.